{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:22:50Z","timestamp":1755220970070,"version":"3.43.0"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>There are several comorbidities associated with psoriasis, including genetic disorders such as hereditary hemochromatosis, which can lead to organ damage secondary to iron overload. Herein, we report the case of a 38-year-old Chinese man with hereditary hemochromatosis who received secukinumab for the treatment of severe psoriasis. Follow-up after 3\u202fmonths showed that the patient\u2019s lesions had almost resolved and remained well-controlled for 2\u202fyears without any reported side effects. Patients with psoriasis and hereditary hemochromatosis have limited treatment options due to the effects of iron overload on the liver, particularly because it may increase the risk of hepatocellular carcinoma. Interleukin-17A (IL-17A) inhibitors, such as the secukinumab used in this case, may benefit these patients.<\/jats:p>","DOI":"10.3389\/fmed.2025.1594640","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T04:10:23Z","timestamp":1754626223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Secukinumab for the treatment of severe psoriasis in a patient with hereditary hemochromatosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Yingzhe","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingjiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.12998\/wjcc.v8.i23.5962","article-title":"Genetic diagnosis history and osteoarticular phenotype of a non-transfusion secondary hemochromatosis","volume":"8","author":"Ruan","year":"2020","journal-title":"World J Clin Cases"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13023-022-02464-w","article-title":"Dermatologic manifestations in patients with the Hermansky-Pudlak syndrome types 1 and 3","volume":"17","author":"Santos Malave","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s13023-021-02020-y","article-title":"Correlation of genotype and phenotype in 32 patients with hereditary hemochromatosis in China","volume":"16","author":"Wu","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3324\/haematol.2016.160432","article-title":"Pathophysiological consequences and benefits of HFE mutations: 20 years of research","volume":"102","author":"Hollerer","year":"2017","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/gim.2015.140","article-title":"The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data","volume":"18","author":"Wallace","year":"2016","journal-title":"Genet Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/09546634.2018.1529381","article-title":"Secukinumab efficacy in the treatment of nail psoriasis: a case series","volume":"29","author":"Pistone","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11626-023-00770-6","article-title":"Secukinumab plays a synergistic role with starvation therapy in promoting autophagic cell death of hepatocellular carcinoma via inhibiting IL-17A-increased BCL2 level","volume":"59","author":"Tang","year":"2023","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jhep.2019.12.016","article-title":"IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease","volume":"72","author":"Ma","year":"2020","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbrc.2018.12.103","article-title":"IL-17A inhibits autophagic activity of HCC cells by inhibiting the degradation of Bcl2","volume":"509","author":"Li","year":"2019","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1594640\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T04:10:24Z","timestamp":1754626224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1594640\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":11,"alternative-id":["10.3389\/fmed.2025.1594640"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1594640","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"1594640"}}